Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 206 от 240

Активно (без набиране) Фаза 1/2

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Intrahepatic Cholangiocarcinoma (Icc) Cholangiocarcinoma Other Solid Tumors, Adult FGFR2 Gene Fusion/Rearrangement +8

This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.

Начало: 22.01.2025 Край: 01.06.2027 Възраст: от 18 г.

Canada, United States Cogent Biosciences, Inc. NCT06777316

Активно (без набиране)

A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older

Community-Acquired Pneumonia (CAP)

The purpose of this study is to learn about how well the Prevnar 20 vaccine (PCV20) stops invasive pneumococcal disease (a group of severe infections caused by a bacteria called Streptococcus pneumoniae), pneumococcal pneumonia (a bacterial lung disease caused by the germ Streptococcus pneumoniae), all-cause pneumonia (pneumonia caused by any germ including bacteria, a virus, or a fungus), and lower respiratory tract infection (infection of the lower airways in the lung) in people 65 years and older. This study will use a database of people who have Medicare insurance with names and other identifying information removed. This study will include people who: * are 65 years and older, * live in one of the 50 United States or Washington DC, and * are enrolled in Medicare Fee-for-Service Parts A and B for at least 1 year. The study uses data that is already being collected and no treatment or vaccine will be given in the study. People that fit the description above will be followed in the Medicare database for about two years. Their information will be reviewed to see if they had vaccines for pneumonia or had certain health events, such as pneumonia or lower respiratory tract infection. The experiences of people that received Prevnar 20 will be compared to the experiences of people that did not receive the vaccine. This will help to show how well Prevnar 20 works at stopping invasive pneumococcal disease, pneumococcal pneumonia, all-cause pneumonia, and lower respiratory tract infection.

Начало: 20.01.2025 Край: 30.10.2026 Възраст: от 65 г.

United States Pfizer NCT06782282

Активно (без набиране) Фаза 1

Aging Resilience Through Microbiota Optimization and Regulation

Resilience Cognitive Function and Well-Being Muscle Function, Handgrip Strength Test Insulin Sensitivity

Sarcopenia, characterized by the progressive loss of muscle mass and strength in older adults, is a key factor in health deterioration. It affects 15% of people between 65 and 80 years old and over 50% of those over 80, compromising autonomy and increasing the risk of diseases. Sarcopenia not only impacts muscle function but also bone health, mobility, and is associated with cardiometabolic diseases and cognitive decline. It has been proposed that changes in the gut microbiota in aging individuals, known as gut dysbiosis, contribute to sarcopenia. Species diversity decreases, and bacterial representation is altered, which could impair muscle function through various pathways, such as mitochondrial dysfunction, chronic inflammation, and disruption of protein synthesis. Muscle function loss is strongly associated with cognitive and metabolic impairment in older adults. Recently, it has been demonstrated that fecal microbiota transplantation (FMT) is an effective procedure for modulating gut microbiota and has proven highly effective in managing cases of Clostridium difficile-associated chronic diarrhea. The main objective of this project is to carry out FMT from young, physically active donors to a cohort of older adults to evaluate its effect on muscle, cognitive, and metabolic function. Why donors who exercise? There is growing evidence that gut microbiota diversity is increased in young, physically active individuals. The FMT is planned to be administered through lyophilized microbiota capsules. By restoring microbial diversity, it is expected to improve the quality and function of skeletal muscles, leading to greater cognitive and metabolic resilience. This project has great potential to develop an innovative approach for treating highly debilitating diseases that affect older adults, based on the lyophilization and encapsulation of gut microbiota from young, trained donors, which can be easily stored in a conventional freezer. Due to the high percentage of older adults worldwide and the high prevalence of sarcopenia within this age group, the aim of the project is to address a significant public health issue with a large target population eager for options to promote muscle health, functional autonomy, as well as cognitive and metabolic well-being.

Начало: 10.01.2025 Край: 30.09.2027 Възраст: 65–84 г.

Chile Gonzalo Jorquera, PhD NCT06649981

Активно (без набиране) Фаза 2

A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

Rheumatoid Arthritis

This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA).

Начало: 10.01.2025 Край: 01.09.2027 Възраст: от 18 г.

Argentina, Bulgaria, Czechia +8 Immunovant Sciences GmbH NCT06754462

Активно (без набиране) Фаза 3

Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

Congenital Hemophilia A

For bridging the available global clinical data of rVIII-SingleChain, with the Chinese population, the aim of this study in China is to investigate the pharmacokinetics (PK) of rVIII-SingleChain after an initial and repeat dose and to assess efficacy and safety during 2 to 3 times weekly prophylaxis treatment with rVIII-SingleChain in male Chinese PTPs with severe hemophilia A (FVIII activity less than \[\

Начало: 09.01.2025 Край: 26.10.2026 Възраст: до 65 г.

China CSL Behring NCT06738485

Активно (без набиране)

Cervical Lordosis: Imaging Position and Measurement

Cervical Lordosis Lordosis; Postural Radiographic Study Radiographic Outcomes +2

This retrospective cross-sectional study aims to compare cervical lordosis measurements obtained from standing lateral radiographs and supine magnetic resonance imaging (MRI) in individuals without structural cervical pathology. The study also evaluates the independent contribution of T1 slope to cervical alignment and investigates whether imaging modality significantly alters measured lordosis values.

Начало: 01.01.2025 Край: 01.06.2026 Възраст: 18–65 г.

Turkey (Türkiye) Medipol University NCT07541586

Активно (без набиране) Фаза 1/2

ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial

AML

To demonstrate the efficacy of targeted and tailored sequential therapy in patients with AML.

Начало: 30.12.2024 Край: 31.07.2028 Възраст: 18–55 г.

United States M.D. Anderson Cancer Center NCT06664879

Активно (без набиране) Фаза 2

Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID

Post-COVID Condition Fatigue Symptom

The primary purpose of this phase 2a study is to compare the efficacy of abrocitinib to placebo in improving severe fatigue in non-hospitalized adults with symptomatic Post-COVID Condition (PCC) (also called Long COVID). We are also interested in learning if abrocitinib is effective in improving overall health status in people suffering from severe fatigue from PCC. Eligible participants with a confirmed history of COVID19 infection who also have PCC according to the World Health Organization definition, will be randomized to receive abrocitinib at a dose of 50 mg, 100 mg, or placebo by mouth daily for 12 weeks (84 days).

Начало: 27.12.2024 Край: 30.09.2026 Възраст: 18–65 г.

United States Beth Israel Deaconess Medical Center NCT06597396

Активно (без набиране) Фаза 1

Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors

Solid Tumors Colorectal Cancer

The purpose of this study is to evaluate the safety and early clinical activity of M9140 in Chinese participants with locally advanced or metastatic colorectal cancer (CRC).

Начало: 20.12.2024 Край: 30.09.2026 Възраст: от 18 г.

China Merck Healthcare KGaA, Darmstadt, Germany, an affiliate NCT06806046

Активно (без набиране)

Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

The purpose of this study is to estimate the prevalence, demographic, and clinical characteristics of PKD1/2 gene variant groups in the ADPKD population.

Начало: 19.12.2024 Край: 31.12.2026 Възраст: 12–65 г.

Belgium, Canada, France +6 Vertex Pharmaceuticals Incorporated NCT06747572

Активно (без набиране) Фаза 3

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Pneumococcal Immunization

This study is a Phase 3, randomized, modified double-blind study which aims to measure whether PCV21 vaccine (investigational pneumococcal conjugate vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20-valent pneumococcal vaccine (Prevnar 20, licensed pneumococcal conjugate vaccine) when they are administered with routine pediatric vaccines in infants aged from approximately 2 months (42 to 89 days). The study duration per participant will be up to approximately 19 months. The study vaccines (either PCV21 or 20-valent pneumococcal vaccines) will be administered at approximately 2, 4, 6 and 12 to 15 months of age. Routine pediatric vaccines will be given at the same timepoints. There will be 6 study visits: -Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age until 15 months of age, V06 separated from V05 by 30 days.

Начало: 18.12.2024 Край: 17.05.2027 Възраст: 42–89 г. Превенция

Australia, Honduras, Puerto Rico +3 Sanofi Pasteur, a Sanofi Company NCT06736041

Активно (без набиране)

Study of Patient With Frequent COPD Exacerbations

Chronic Obstructive Pulmonary Disease (COPD)

This Study is a multicenter, non-interventional, observational, ambispective (retrospective-prospective) study to evaluate clinical and demographic characteristics, approaches to therapy in outpatients with COPD and frequent exacerbations in the Russian Federation. Planned number of Study site is 35 outpatient centers with experience of treatment of COPD with frequency exacerbations in about 30 regions in Russia.

Начало: 16.12.2024 Край: 30.06.2026 Възраст: 18–100 г.

Russia AstraZeneca NCT07221981

Активно (без набиране)

Innovative Spinopelvic Solutions With Real-World Evidence

Sacroiliac Joint Dysfunction Sacroiliac Joint Pain

INSPIRE is a prospective decentralized study evaluating post-operative health outcomes in patients who undergo a procedure using implants manufactured by SI-BONE.

Начало: 15.12.2024 Край: 01.12.2034 Възраст: от 21 г.

United States SI-BONE, Inc. NCT06706908

Активно (без набиране) Фаза 2

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Idiopathic Pulmonary Fibrosis (IPF)

The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com

Начало: 09.12.2024 Край: 01.06.2027 Възраст: от 40 г. Лечение

Argentina, Australia, Austria +11 Vicore Pharma AB NCT06588686

Активно (без набиране)

A Future Thinking Intervention for Comorbid Tobacco Use Disorder and Bipolar Disorder

Bipolar Disorder Tobacco Use Disorder

Future Self-BD is a 6-session virtual intervention that encourages participants to vividly generate personal and positive future events that they anticipate may be benefited by smoking cessation. Each session will be conducted on HIPAA-compliant Zoom and led by the PI (Dr. Gold).

Начало: 06.12.2024 Край: 30.04.2028 Възраст: от 18 г.

United States Massachusetts General Hospital NCT06609902

Активно (без набиране) Фаза 3

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

Multiple System Atrophy

The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).

Начало: 03.12.2024 Край: 25.10.2029 Възраст: 40–75 г. Лечение

Australia, Canada, France +7 H. Lundbeck A/S NCT06706622

Активно (без набиране)

Effect of Feeding Jejunostomy on Sarcopenia in Patients With Esophageal Cancer

Esophageal Cancer Esophageal Carcinoma Sarcopenia Feeding Tube

Participants were diagnosed with esophageal cancer needing chemo- or radiochemotherapy before the potentially curing surgery consisting of esophagectomy. At the time of diagnosis, in all participants, a laparoscopy to complete staging was performed. In some patients, a feeding jejunostomy tube (FJT) was placed at the time of staging laparoscopy; in others, the FJT was placed at the time of esophagectomy. A common risk factor for higher morbidity and mortality is sarcopenia, a condition associated with low skeletal muscle. This study aims to determine whether the timing of the FJT placement affects the progress of sarcopenia.

Начало: 30.11.2024 Край: 30.06.2026 Възраст: от 18 г.

Switzerland Stefan Gutknecht NCT06712706

Активно (без набиране)

Pain Self-Management and Treatment Engagement for Patients Taking Opioids

Chronic Pain Opioid Use Disorder Opioid Misuse and Addiction

The goal of this study is to learn if Pain Self-Management (PSM) can improve chronic pain care in individuals with opioid misuse or opioid use disorder (OUD) The main questions it aims to answer are: * Does PSM help participants manage their chronic pain more effectively? * Does PSM help participants engage in treatment for opioid use? Researchers will compare PSM to standard care to see if PSM is effective in managing chronic pain and engagement in treatment. Participants will: * Take part in the PSM program or receive standard care for 12 weeks after enrolling in the study * Complete surveys every 3 months for 9 months (total of 4 visits) Participants will receive compensation for participating in the study. There are risks associated with participating in the study, including breach of confidentiality and psychological distress caused by discussing difficult topics.

Начало: 25.11.2024 Край: 31.12.2026 Възраст: от 18 г.

United States University of Pittsburgh NCT06855732

Активно (без набиране)

Avalus Ultra Post-Approval Study (PAS)

Aortic Valve Disease

The purpose of this study is to characterize the safety and effectiveness of the Medtronic Avalus Ultra aortic valve bioprosthesis in patients with aortic valve disease.

Начало: 20.11.2024 Край: 01.11.2026 Възраст: от 18 г.

United States Medtronic Cardiac Surgery NCT06506903

Активно (без набиране)

Stryker Facial iD Universal Plate Configurator: A Retrospective Post Market Follow Up

Mandibular Fractures Facial Fracture Maxilla Fracture Orthognathic Surgical Procedures

A retrospective post market follow up to confirm safety and performance of Stryker's Facial iD Universal Plate Configurator (UPC) implants in the clinical setting. The study is performed to confirm the product's performance and safety by systematically collecting clinical data on its use.

Начало: 18.11.2024 Край: 31.05.2026

United States Stryker Craniomaxillofacial NCT07245810

1 … 204 205 206 207 208 … 240